Literature DB >> 23376811

Porcine model to evaluate local tissue tolerability associated with subcutaneous delivery of protein.

D W Kang1, D A Oh, G Y Fu, J M Anderson, M L Zepeda.   

Abstract

INTRODUCTION: The conversion from intravenous (IV) to subcutaneous (SC) delivery of biotherapeutics has increased in recent years. Some of the reasons for this shift in route of delivery are due to patient convenience, reduced adverse systemic effects, lack of a need for vascular access, and reduced cost of patient care, which ultimately lead to improved patient quality of life. One caveat to SC delivery is the limited volumes that can be administered at a single site and the associated local tolerability. To characterize factors that affect subcutaneous delivery of large volumes of therapeutic proteins, a porcine model was developed. Model endpoints included measurement of interstitial pressure, assessment of local skin visco-elasticity, and the qualitative assessment of local infusion sites.
METHODS: Immunoglobulin G (IgG) was subcutaneously infused into the abdominal region of Yucatan miniature swine. Changes in interstitial pressure were measured, using an in-line pressure transducer, during and after infusions. Additionally, pre- and post-infusion changes in local skin visco-elasticity were measured using a Cutometer®. Lastly, infusion sites were assessed for post-infusion local skin reactions such as erythema and swelling. Similar assessments were made following SC IgG delivery with the permeation enhancer recombinant human hyaluronidase PH20 (rHuPH20).
RESULTS: Subcutaneous infusions of IgG, in the presence of rHuPH20, significantly reduced average interstitial pressures by 55% during the infusion period and by 67% during the post-infusion period, compared to the control. Infusions in the presence of rHuPH20 also maintained better local skin elasticity as seen by a 42% increase in local skin pliability compared to the control. Finally, infusions with rHuPH20 resulted in an 80% reduction in swelling area compared to the control. DISCUSSION: A large animal model was developed that incorporates both quantitative and qualitative assessment methods to aid in understanding SC delivery of proteins.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376811     DOI: 10.1016/j.vascn.2013.01.011

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  7 in total

1.  Tolerability of High-Volume Subcutaneous Injections of a Viscous Placebo Buffer: A Randomized, Crossover Study in Healthy Subjects.

Authors:  Clapton Dias; Bassam Abosaleem; Caroline Crispino; Bing Gao; Adam Shaywitz
Journal:  AAPS PharmSciTech       Date:  2015-02-19       Impact factor: 3.246

2.  Anatomical, physiological, and experimental factors affecting the bioavailability of sc-administered large biotherapeutics.

Authors:  Anas M Fathallah; Sathy V Balu-Iyer
Journal:  J Pharm Sci       Date:  2014-11-19       Impact factor: 3.534

3.  Clinical Immunogenicity of rHuPH20, a Hyaluronidase Enabling Subcutaneous Drug Administration.

Authors:  Sanna Rosengren; Samuel S Dychter; Marie A Printz; Lei Huang; Richard I Schiff; Hans-Peter Schwarz; John K McVey; Fred H Drake; Dan C Maneval; Don A Kennard; Gregory I Frost; Barry J Sugarman; Douglas B Muchmore
Journal:  AAPS J       Date:  2015-05-13       Impact factor: 4.009

Review 4.  Optimizing the Bioavailability of Subcutaneously Administered Biotherapeutics Through Mechanochemical Drivers.

Authors:  D S Collins; L C Kourtis; N R Thyagarajapuram; R Sirkar; S Kapur; M W Harrison; D J Bryan; G B Jones; J M Wright
Journal:  Pharm Res       Date:  2017-07-13       Impact factor: 4.200

5.  Novel cannula design improves large volume auto-injection rates for high viscosity solutions.

Authors:  Bruce C Roberts; Christopher Rini; Rick Klug; Douglas B Sherman; Didier Morel; Ronald J Pettis
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

6.  Clinical Evaluation of an Investigational 5 mL Wearable Injector in Healthy Human Subjects.

Authors:  Wendy D Woodley; Wen Yue; Didier R Morel; Audrey Lainesse; Ronald J Pettis; Natasha G Bolick
Journal:  Clin Transl Sci       Date:  2021-03-25       Impact factor: 4.689

7.  Clinical evaluation of large volume subcutaneous injection tissue effects, pain, and acceptability in healthy adults.

Authors:  Wendy D Woodley; Didier R Morel; Diane E Sutter; Ronald J Pettis; Natasha G Bolick
Journal:  Clin Transl Sci       Date:  2021-11-10       Impact factor: 4.689

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.